Suppr超能文献

成人妊娠并发症的药物治疗:IV期临床试验综述。

Pharmacological treatment of pregnancy complications in adults: An overview of phase IV clinical trials.

作者信息

Allehyani Rawan F, Alsehli Atheer A, Saggat Raghad Z, Aldurdunji Mohammed M, Alorfi Nasser M

机构信息

College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

出版信息

Medicine (Baltimore). 2025 Jan 31;104(5):e41322. doi: 10.1097/MD.0000000000041322.

Abstract

The aim of this review was to provide a review of the pharmacological treatments for pregnancy complications in adults. This review analyzed medications used for pregnancy complications in phase IV clinical trials based on the ClinicalTrials.gov database. The search included completed trials only. As of September 1, 2023, a total of 29,654 phase IV clinical trials were identified, of which 298 were related to pregnancy complications. Of these, 24 clinical trials met the inclusion criteria for the current study. In the 24 included clinical trials, we found 9 trials for overactive bladder with 5005 participants in total, 236 of which had adverse effects from the drugs used. Six trials for preeclampsia were conducted on 663 participants, with only 1 adverse drug effect reported. Three trials each were conducted on urinary tract infections and gestational diabetes mellitus (115 and 656 participants, respectively) without any adverse drug effects reported. One trial each focused on anemia, dystocia, and placentation disorders (80, 1003, and 14 participants, respectively) without any adverse drug effects reported. The trials reported minimal adverse drug effects, suggesting potential effectiveness and safety in managing these complications. While the trials mentioned minimal adverse effects, close monitoring and individualized patient care are essential, as are evaluating the risk-benefit ratio and the specific circumstances of each patient.

摘要

本综述的目的是对成人妊娠并发症的药物治疗进行综述。本综述基于ClinicalTrials.gov数据库分析了IV期临床试验中用于妊娠并发症的药物。检索仅包括已完成的试验。截至2023年9月1日,共识别出29654项IV期临床试验,其中298项与妊娠并发症相关。其中,24项临床试验符合本研究的纳入标准。在这24项纳入的临床试验中,我们发现9项关于膀胱过度活动症的试验,共有5005名参与者,其中236人出现了所用药物的不良反应。对663名参与者进行了6项子痫前期试验,仅报告了1例药物不良反应。分别对115名和656名参与者进行了3项关于尿路感染和妊娠期糖尿病的试验,均未报告任何药物不良反应。各有1项试验分别关注贫血、难产和胎盘植入障碍(分别有80名、1003名和14名参与者),均未报告任何药物不良反应。这些试验报告的药物不良反应极少,表明在管理这些并发症方面具有潜在的有效性和安全性。虽然试验提到不良反应极少,但密切监测和个体化的患者护理至关重要,评估风险效益比以及每个患者的具体情况也同样重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1aa/11789866/c1c9303e24dd/medi-104-e41322-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验